Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07632820 · ClinicalTrials.gov registry record · Phase 4
Erector Spinae Plane Block Versus Trigger Point Injection for Chronic Thoracic Myofascial Pain
A Phase 4 study, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 76
- Enrollment target
NCT07632820: Recruiting Phase 4 study, sponsored by Mayo Clinic.
NCT07632820 is a Phase 4 study that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 76 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07632820, a Phase 4 study, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 76 participants
- Enrollment target
Study Summary
Chronic thoracic (mid-back) pain can be difficult to treat, and there is limited evidence to guide the use of injection therapies for pain arising from muscles and surrounding soft tissues. Two commonly used treatments are trigger point injections (TPI) and erector spinae plane (ESP) blocks, but no studies have directly compared their effectiveness for chronic thoracic myofascial pain. The purpose of this study is to compare pain relief, physical function, emotional well-being, patient satisfaction, and safety following treatment with either an ESP block or TPI. Participants will be randomly assigned to receive one of the two treatments. Researchers will follow participants for up to 12 weeks after the procedure and collect information through questionnaires and pain assessments.
Primary Outcome
A Numeric Rating Scale (NRS) for pain is a patient-reported item regarding the level of pain experienced and is measured on a Likert scale from 0 to 10, where 0 represents "no pain" and 10 represents "the worst pain imaginable".
Interventions
- DRUG Erector Spinae Plane (ESP) Block with 0.5% Plain Bupivacaine
- DRUG Trigger Point Injection (TPI) with 0.5% Plain Bupivacaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2029-08-30 |
| Phase | Phase 4 |
What NCT07632820 shows while recruiting
NCT07632820 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Erector Spinae Plane (ESP) Block with 0.5% Plain Bupivacaine is the first listed.
NCT07632820 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07632820 about?
NCT07632820 is a clinical study titled "Erector Spinae Plane Block Versus Trigger Point Injection for Chronic Thoracic Myofascial Pain". Chronic thoracic (mid-back) pain can be difficult to treat, and there is limited evidence to guide the use of injection therapies for pain arising from muscles and surrounding soft tissues. Two commonly used treatments are trigger point injections (TPI) and erector spinae plane (ESP) blocks, but no ...
What is the current status of trial NCT07632820?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 76 participants. The study started on 2026-08-01. Estimated completion is 2029-08-30.
What interventions are being tested in trial NCT07632820?
The interventions under investigation include: Erector Spinae Plane (ESP) Block with 0.5% Plain Bupivacaine (DRUG), Trigger Point Injection (TPI) with 0.5% Plain Bupivacaine (DRUG).
Who is sponsoring clinical trial NCT07632820?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07632820's enrollment target sits among peer trials
76 994th of 2000 higher than 999 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI